DRR168599
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.350
- OXIDATIVE_PHOSPHORYLATION+0.310
- WNT_BETA_CATENIN_SIGNALING+0.240
- DNA_REPAIR+0.180
- MYC_TARGETS_V2+0.170
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.150
- ADIPOGENESIS+0.110
- ESTROGEN_RESPONSE_EARLY+0.090
- HEME_METABOLISM+0.070
- PEROXISOME+0.070
Top 10 suppressed
- ANGIOGENESIS-0.480
- INFLAMMATORY_RESPONSE-0.480
- ALLOGRAFT_REJECTION-0.460
- E2F_TARGETS-0.460
- G2M_CHECKPOINT-0.460
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.450
- IL6_JAK_STAT3_SIGNALING-0.400
- COMPLEMENT-0.380
- KRAS_SIGNALING_UP-0.370
- SPERMATOGENESIS-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-1357 | Med | Medulloblastoma | 0.844 |
| 2 | 308a5759-8930-433f-8d11-4c3da6ed0e29 | — | — | 0.839 |
| 3 | TCGA-DK-A1AG-01A-11R-A13Y-07 | — | — | 0.837 |
| 4 | MDT-AP-0402 | Med | Medulloblastoma | 0.833 |
| 5 | SRR12202454 | — | — | 0.832 |
| 6 | TCGA-21-1078-01A-01R-0692-07 | — | cohortSQ1 | 0.830 |
| 7 | TCGA-95-7948-01A-11R-2187-07 | — | cohortA1 | 0.827 |
| 8 | R165 | — | — | 0.822 |
| 9 | MBCProject_0004_T1_RNA | — | C | 0.818 |
| 10 | MDT-AP-1207 | Med | Medulloblastoma | 0.816 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.350 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.310 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.240 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.180 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.170 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.150 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.110 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.090 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.070 | Temsirolimus | — uncovered |
| PEROXISOME | 0.070 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.030 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.020 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.020 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.010 | Inavolisib | — uncovered |